Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics
Portfolio Pulse from Benzinga Insights
In the past three months, 12 analysts have rated Sarepta Therapeutics (NASDAQ:SRPT), with most being somewhat bullish. The average 12-month price target is $177.83, a slight decline from previous estimates. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Sarepta's recent revenue growth and net margin are strong, but its ROE is below industry averages.
October 04, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sarepta Therapeutics has received 12 analyst ratings in the last three months, mostly somewhat bullish. The average price target is $177.83, slightly down from previous estimates. Analysts have adjusted ratings and targets, reflecting market conditions and company performance. Sarepta's revenue growth and net margin are strong, but its ROE is below industry averages.
The mixed analyst ratings and slight decline in average price target suggest a neutral short-term impact on SRPT's stock price. While the company's revenue growth and net margin are strong, the below-average ROE indicates potential challenges. The overall sentiment is somewhat bullish, but the adjustments in price targets reflect caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100